CD4 and columnar cell hyperplasia of the breast: However, in jurisdictions whose NBS programs incorporate TSH and FT4/T4 measurements, the prevalence of ICCH was shown to be higher, ranging from 33% to 40% of patients with CCH (15, 18, 20, 21).